Global Daridorexant Market Strategic Research Report

Scope of the Report

The global Daridorexant market size is predicted to grow from US$ 179 million in 2025 to US$ 1,050 million in 2032; it is expected to grow at a CAGR of 29.1% from 2026 to 2032.

Daridorexant, sold under the brand name Quviviq, is a medication used to treat insomnia. It is an orexin receptor antagonist, specifically targeting both OX1 and OX2 receptors. This dual mechanism helps regulate sleep-wake cycles, making it effective for improving sleep onset and maintenance. Unlike benzodiazepines or Z-drugs, daridorexant does not interact with GABA receptors, offering a distinct way to manage sleep disorders.

The medication is taken orally and has a relatively short elimination half-life of around 8 hours, with a peak effect occurring within 1 to 2 hours after administration. Common side effects include headache, somnolence (sleepiness), and fatigue. Daridorexant was approved for use in the United States in January 2022 and became available in May 2022. It was also approved in the European Union in April 2022, marking the first orexin receptor antagonist to be available there. However, it is classified as a Schedule IV controlled substance in the United States, indicating a modest potential for misuse.

Daridorexant provides an alternative to traditional sleep medications, offering a distinct mechanism of action that may reduce the risk of dependence and tolerance associated with other sleep aids.In 2024, global sales of Daridorexant reached 3.94 million tablets, with an average unit price of USD 17.56 per tablet and an average gross profit margin of 71.2%.

In the U.S. and Europe, Daridorexant has entered a phase of rapid commercial expansion, supported by favorable clinical differentiation and growing physician adoption. Within the European Union, it is the most recent DORA approved by the EMA for improving both nighttime sleep and daytime functioning—an indication that broadens its clinical appeal beyond sleep onset and maintenance alone. Compared with other DORAs, its pharmacokinetic profile and well-balanced efficacy-safety ratio contribute to higher treatment adherence and positive real-world outcomes.

From a commercial standpoint, Daridorexant’s global rollout reflects a strategic blend of licensing, distribution, and market access initiatives. Regional partnerships enable efficient regulatory navigation and localized market penetration, ensuring coverage across hospitals, retail pharmacies, and online prescription platforms. Reimbursement listings in select countries further enhance patient accessibility, reinforcing uptake momentum. The integration of pharmacovigilance and patient-reported outcomes into post-marketing surveillance also supports sustained physician confidence and long-term safety validation.

Market uptake has been strongest in North America, Western Europe, and Japan, where supportive healthcare infrastructure and awareness campaigns accelerate adoption. In emerging markets such as China, Daridorexant’s entry underscores the expanding recognition of DORA-based therapeutics as the next-generation standard for insomnia care. Continued emphasis on education, real-world data generation, and stable supply chains will be critical to maintaining its growth trajectory.

Overall, Daridorexant exemplifies the evolution of insomnia therapeutics toward mechanism-driven, safety-conscious innovation. Its combination of differentiated pharmacology, robust clinical data, and strategic commercialization positions it as a leading agent in the global sleep medicine landscape—poised to define the post-benzodiazepine era of pharmacological sleep management.

This report presents a comprehensive overview of the global Daridorexant market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 25mg
• 50 mg

Segment by Dosage Form

• Tablets
• Other

Segment by Research Attributes

• Original Drug
• Generic Drug

Segment by Application

• Hospital and Clinic
• Retail Pharmacies
• Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Daridorexant market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hospital and Clinic, Retail Pharmacies, Other evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact